Crinetics Pharmaceuticals

Crinetics Pharmaceuticals company information, Employees & Contact Information

Our mission is to build the leading endocrine company that consistently pioneers new therapeutics to help patients better control their disease and improve their daily lives. Working to accomplish this mission is how we bring our vision to life. For us, that vision is the best possible therapeutics available to all patients with diseases of the endocrine system. We love how that sounds. And we really can’t wait to know how it feels. Notice of Fraudulent Activity for Job Applicants: Please be aware of fraudulent communications from job posting sites or email. Bad actors may try to impersonate Crinetics’ Talent Acquisition team, and their messages may appear legitimate. We strongly recommend you verify all communications you receive about positions at Crinetics. If you are unsure about a posting or email you receive, please contact us at talentacquisition@crinetics.com.

Company Details

Employees
510
Founded
-
Address
6055 Lusk Blvd, San Diego,california 92121,united States
Phone
(760) 274-6963
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
San Diego, California
Looking for a particular Crinetics Pharmaceuticals employee's phone or email?

Crinetics Pharmaceuticals Questions

News

Crinetics Pharmaceuticals to Present Key Clinical Data at NANETS 2025 Annual Meeting on Neuroendocrine Tumors - Quiver Quantitative

Crinetics Pharmaceuticals to Present Key Clinical Data at NANETS 2025 Annual Meeting on Neuroendocrine Tumors Quiver Quantitative

Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 - Yahoo Finance

Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 Yahoo Finance

Crinetics Pharmaceuticals Reports Positive Results for Paltusotine in Treating Surgically Naïve Acromegaly Patients at AACE 2025 - Nasdaq

Crinetics Pharmaceuticals Reports Positive Results for Paltusotine in Treating Surgically Naïve Acromegaly Patients at AACE 2025 Nasdaq

Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire

78,975 Options & 54,475 RSUs — Crinetics Grants to 20 New Hires, Exercise Price $44.93, Oct 10, 2025 - Stock Titan

78,975 Options & 54,475 RSUs — Crinetics Grants to 20 New Hires, Exercise Price $44.93, Oct 10, 2025 Stock Titan

Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025 - Yahoo Finance

Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025 Yahoo Finance

Crinetics Pharmaceuticals Announces Presentation of Key Data on PALSONIFY™ and Atumelnant at ENDO 2025 Meeting - Quiver Quantitative

Crinetics Pharmaceuticals Announces Presentation of Key Data on PALSONIFY™ and Atumelnant at ENDO 2025 Meeting Quiver Quantitative

Nov 6, 2025: Crinetics to Report Q3 2025 Results — Conference Call & Webcast 4:30 p.m. ET - Stock Titan

Nov 6, 2025: Crinetics to Report Q3 2025 Results — Conference Call & Webcast 4:30 p.m. ET Stock Titan

Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire

Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance

Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update Yahoo Finance

Crinetics Expands Team with 27 New Hires, Grants $2M+ in Equity Compensation Package - Stock Titan

Crinetics Expands Team with 27 New Hires, Grants $2M+ in Equity Compensation Package Stock Titan

Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025 - GlobeNewswire

Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025 GlobeNewswire

62,475 Stock Options at $35/Share: Crinetics Pharmaceuticals Awards Inducement Grants to New Hires - Stock Titan

62,475 Stock Options at $35/Share: Crinetics Pharmaceuticals Awards Inducement Grants to New Hires Stock Titan

Crinetics Receives FDA Orphan Drug Designation for - GlobeNewswire

Crinetics Receives FDA Orphan Drug Designation for GlobeNewswire

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update GlobeNewswire

Crinetics Expands Team with 46 New Hires, Grants $3.2M+ in Equity Compensation - Stock Titan

Crinetics Expands Team with 46 New Hires, Grants $3.2M+ in Equity Compensation Stock Titan

Crinetics Earnings: $1.2B War Chest Powers PALSONIFY Launch, FDA Decision Looms in September - Stock Titan

Crinetics Earnings: $1.2B War Chest Powers PALSONIFY Launch, FDA Decision Looms in September Stock Titan

Crinetics Pharmaceuticals Receives FDA Orphan Drug Designation for Atumelnant in Treating Classic Congenital Adrenal Hyperplasia - Quiver Quantitative

Crinetics Pharmaceuticals Receives FDA Orphan Drug Designation for Atumelnant in Treating Classic Congenital Adrenal Hyperplasia Quiver Quantitative

Crinetics Pharmaceuticals Presents New Long-Term Data on PALSONIFY for Acromegaly at ENDO 2025 - Quiver Quantitative

Crinetics Pharmaceuticals Presents New Long-Term Data on PALSONIFY for Acromegaly at ENDO 2025 Quiver Quantitative

Crinetics Pharmaceuticals: Highly Priced Biotech Awaits PDUFA On Acromegaly Drug - Seeking Alpha

Crinetics Pharmaceuticals: Highly Priced Biotech Awaits PDUFA On Acromegaly Drug Seeking Alpha

Crinetics Strengthens Team with $2.4M in Equity Grants: 74,000 Stock Options Plus RSUs for New Talent - Stock Titan

Crinetics Strengthens Team with $2.4M in Equity Grants: 74,000 Stock Options Plus RSUs for New Talent Stock Titan

Breakthrough: Crinetics' Once-Daily Oral PALSONIFY Matches Injectable Treatments in 96-Week Acromegaly Study - Stock Titan

Breakthrough: Crinetics' Once-Daily Oral PALSONIFY Matches Injectable Treatments in 96-Week Acromegaly Study Stock Titan

80% Biomarker Reduction: Crinetics' Breakthrough CAH Drug Atumelnant Receives FDA Orphan Status - Stock Titan

80% Biomarker Reduction: Crinetics' Breakthrough CAH Drug Atumelnant Receives FDA Orphan Status Stock Titan

Crinetics to Unveil Critical Pipeline Updates: New Data on NETs, Graves Disease, and Kidney Disease Programs - Stock Titan

Crinetics to Unveil Critical Pipeline Updates: New Data on NETs, Graves Disease, and Kidney Disease Programs Stock Titan

Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly - GlobeNewswire

Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly GlobeNewswire

Crinetics (CRNX) Stock Skyrockets on FDA Approval – Full 2025 Investor Update - ts2.tech

Crinetics (CRNX) Stock Skyrockets on FDA Approval – Full 2025 Investor Update ts2.tech

Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer - Yahoo Finance

Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer Yahoo Finance

Breakthrough: First Oral Acromegaly Drug Hits Major EU Milestone with Dual Regulatory Wins - Stock Titan

Breakthrough: First Oral Acromegaly Drug Hits Major EU Milestone with Dual Regulatory Wins Stock Titan

Crinetics Announces Positive Topline Results From Phase 2 - GlobeNewswire

Crinetics Announces Positive Topline Results From Phase 2 GlobeNewswire

Crinetics Pharmaceuticals: Attractive Speculative Bet On Market Weakness (NASDAQ:CRNX) - Seeking Alpha

Crinetics Pharmaceuticals: Attractive Speculative Bet On Market Weakness (NASDAQ:CRNX) Seeking Alpha

Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly - GlobeNewswire

Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly GlobeNewswire

Crinetics' Breakthrough Oral Acromegaly Drug Advances as FDA Accepts NDA for First-in-Class Treatment - Stock Titan

Crinetics' Breakthrough Oral Acromegaly Drug Advances as FDA Accepts NDA for First-in-Class Treatment Stock Titan

Crinetics Pharmaceuticals to Showcase Novel Nonpeptide Drug Conjugate Platform and Phase 2 Data for Paltusotine at NANETS 2024 - Quiver Quantitative

Crinetics Pharmaceuticals to Showcase Novel Nonpeptide Drug Conjugate Platform and Phase 2 Data for Paltusotine at NANETS 2024 Quiver Quantitative

EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner - Yahoo Finance

EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner Yahoo Finance

Crinetics Pharmaceuticals Expanding - San Diego Business Journal

Crinetics Pharmaceuticals Expanding San Diego Business Journal

Crinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech - Seeking Alpha

Crinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech Seeking Alpha

Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement - GlobeNewswire

Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement GlobeNewswire

Crinetics Expands into New HQ - San Diego Business Journal

Crinetics Expands into New HQ San Diego Business Journal

Crinetics Announces Positive Initial Findings at ENDO 2024 - GlobeNewswire

Crinetics Announces Positive Initial Findings at ENDO 2024 GlobeNewswire

Crinetics Stock Soars on Study Results - San Diego Business Journal

Crinetics Stock Soars on Study Results San Diego Business Journal

Radionetics Oncology Emerges from Crinetics Pharmaceuticals - GlobeNewswire

Radionetics Oncology Emerges from Crinetics Pharmaceuticals GlobeNewswire

Top Crinetics Pharmaceuticals Employees

  • Andy Giglio

    Andy Giglio

    n/a

    Washington Dc-Baltimore Area, United States, United States
    1
    yahoo.com
  • Bonnie Lam

    Bonnie Lam

    n/a

    San Francisco Bay Area, United States
    5
    ascendispharma.com, gmail.com, gmail.com, apnicure.com, crinetics.com
  • Matthew Fust

    Matthew Fust

    Independent Advisor To Life Sciences…

    San Francisco, California, United States, United States
    10
    crinetics.com, onyx-pharm.com, dermira.com, ultragenyx.com, gmail.com, jazzpharmaceuticals.com, perlegen.com, onyx.com, arsenalbio.com, onyx-pharm.com

    4 +141560XXXXX

  • Annette Dowsing

    Annette Dowsing

    n/a

    San Diego, California, United States, United States
    7
    myovant.com, abbott.com, lincolnxing.org, bio-rad.com, alere.com, talenttree.com, staffingforce.com

    4 +185884XXXXX

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant